Schistosomiasis vaccines: Research to development

Parasitology Today

Volumn 14, Issue 3, 1998, Pages 99-104

  Bergquist, V Robert ^a   Colley, Dan G ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SCHISTOSOMA VACCINE;

DRUG RESEARCH; EGYPT; IMMUNE RESPONSE; INTERNATIONAL COOPERATION; REVIEW; SCHISTOSOMIASIS; SYMPOSIUM;

EID: 0032030745     PISSN: 01694758     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-4758(97)01207-6     Document Type: Article

References (17)

1. 1 Bergquist, R. (1995) Controlling schistosomiasis by vaccination: a realistic option? Parasitol. Today 11, 191-194
2. 2 Dunne, D.W. et al. (1995) Prospects for immunological control of schistosomiasis. Lancet 345, 1488-1492
3. 3 Bergquist, N.R. (1995) Schistosomiasis vaccine development: approaches and prospects. Mem. Inst. Oswaldo Cruz 90, 221-227
4. 4 Hagan, P. and Gryseels, B. (1994) Schistosomiasis research and the European Community. Trop. Geogr. Med. 46, 259-268
5. 5 Bjorvatn, B. ed. (1996) The European Commission COST/ STD-3 Initiative on European Vaccine Research Reports of the Expert Panels. Vaccine 14, 579-734
6. 6 Chan, M-S. et al. (1997) Human schistosomiasis: potential long-term consequences of vaccination programmes. Vaccine 15, 1445-1450
7. 7 Riveau, G. and Capron, A. (1996) in Concepts in Vaccine Development (Kaufmann, S., ed.), pp 501-532, Walter de Gruyter
8. 8 Boulanger, D. et al. (1995) Vaccination of Patas monkeys experimentally infected with Schistosoma haematobium using a recombinant gluthathione S-transferase cloned from S. mansoni. Parasite Immunol. 17, 361-369
9. 9 Cox, J.C. and Coulter A.R. (1997) Adjuvants - a classification and review of their modes of action. Vaccine 15, 248-256
10. 10 Pearce, E.J. et al. (1996) IL-4 in schistosomiasis. Exp. Parasitol. 84, 295-299
11. 11 Coulson, P.S. and Wilson, R.A. (1997) Recruitment of lymphocytes to the lung through vaccination enhances the immunity of mice exposed to irradiated schistosomes. Infect. Immun. 65, 42-48
12. 12 Olveda, R.M. et al. (1996) Schistosomiasis japonica in the Philippines: the long-term impact of population-based chemotherapy on infection, transmission, and morbidity. J. Infect. Dis. 174, 163-172
13. 13 Pearce, E.J. et al. (1988) Induction of protective immunity against Schistosoma mansoni by vaccination with schistosome paramyosin (Sm97), a nonsurface parasite antigen. Proc. Natl. Acad. Sci. U.S.A. 85, 5678-5682.
14. 14 Soisson, L.M. et al. (1992) Induction of protective immunity in mice using a 62-kDa recombinant fragment of a Schistosoma mansoni surface antigen. J. Immunol. 149, 3612-3620
15. 15 Reynolds, S.R. et al. (1994) T and B epitope determination and analysis of multiple antigenic peptides for the S. mansoni experimental vaccine triose-phosphate isomerase. J. Immunol. 152, 193-200
16. 16 Reynolds, S.R. et al. (1992) T and B cell epitope mapping of Sm23, an integral membrane protein S. mansoni. J. Immunol. 149, 3995-4001
17. 17 Tendler, M. et al. (1996) A Schistosoma mansoni fatty acid-binding protein, Sm14, is the potential basis of a dual-purpose anti-helminth vaccine. Proc. Natl. Acad. Sci. U. S. A. 93, 269-273